Skip to main
DHR

Danaher (DHR) Stock Forecast & Price Target

Danaher (DHR) Analyst Ratings

Based on 18 analyst ratings
Buy
Strong Buy 50%
Buy 33%
Hold 17%
Sell 0%
Strong Sell 0%

Bulls say

Danaher is well-positioned for long-term growth given its strong portfolio of scientific instruments and consumables in the life sciences and diagnostic industries. The recent divestiture of its environmental and applied solutions group, Veralto, allows the company to focus more heavily on its core businesses. The expected close of the Masimo acquisition in 2H 2026 and a broadening bioprocess recovery add to the company's growth potential. The company is actively addressing any challenges in its diagnostic business and is committed to diversity and inclusion in its leadership roles.

Bears say

Danaher is a global science and technology company focused on biotechnology, life sciences, and diagnostics, but its sustainability concerns and recent underperformance in the life science tools market are potential indicators of fundamental issues underlying the company's growth. With an extensive manufacturing footprint and potential challenges in decarbonization, coupled with recent business divestitures and acquisitions, Danaher's growth may face headwinds as it continues to integrate and evolve its business operations. As such, a negative outlook is warranted, and a downside scenario could see materialization in the form of persistent sluggishness in bioprocess equipment demand, decelerating trends in diagnostics, and challenges with future acquisition target selection.

Danaher (DHR) has been analyzed by 18 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 33% recommend Buy, 17% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Danaher and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Danaher (DHR) Forecast

Analysts have given Danaher (DHR) a Buy based on their latest research and market trends.

According to 18 analysts, Danaher (DHR) has a Buy consensus rating as of Sep 15, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $230.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $230.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Danaher (DHR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.